Quit Smoking Today
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Patriotic Lollipops
Patriotic Lollipops Perfect for your July 4th celebrations! To make the centerpiece pictured, see instructions below recipe. Ingredients Hard Candy Recipe (3 batches-one for each color) 1 teaspoon LorAnn Super Strength Flavoring of choice (for each batch) (we used blueberry, raspberry and pina colada) 1/4 teaspoon White Liquid Food Coloring 1/8 teaspoon Sky Blue Gel Food Coloring 1/8 teaspoon Ruby Red Gel Food Coloring 2 Bright Star Lollipop sheet molds 2 Stars Lollipop sheet molds 1 Stars Pieces sheet mold Directions White Lollipops 1. Spray Bright Star and Stars Lollipop molds lightly with cooking spray and insert sucker sticks. 2. Follow directions for making hard candy, adding 1/4 teaspoon of white liquid food coloring when syrup mixture reaches 260°F. Do not stir; boiling action will incorporate color. Continue cooking as directed. 3. When boiling action ceases, stir in flavoring. Allow mixture to rest a few seconds until large bubbles are no longer visible. Pour candy syrup into prepared star molds first, then pour excess into the star pieces mold. 4. Allow candy to harden on the counter for 10 to 15 minutes. Remove from molds. For optimal storage, cover lollipops with sucker bags and secure with twist ties. Store piece candy in an airtight container. Do not refrigerate. Blue Lollipops Follow directions for making the white lollipops, substituting 1/8 teaspoon of the Sky Blue Gel food coloring for the White Liquid color. Share your creations with us on social media! #lorannoils @lorannoils Red Lollipops Follow directions for making the white lollipops, substituting 1/8 teaspoon of the Ruby Red Gel food coloring for the White Liquid color. -
NEISS Coding Manual January 2019
NEISS Coding Manual January 2019 NEISS – National Electronic Injury Surveillance System January 2019 Table of Contents Introduction .............................................................................................................................. 1 General Instructions ................................................................................................................ 1 General NEISS Reporting Rule................................................................................................ 2 Do Report ............................................................................................................................... 2 Definitions ........................................................................................................................... 2 Do Not Report ........................................................................................................................ 3 Specific Coding Instructions ................................................................................................... 4 Treatment Date ...................................................................................................................... 4 Case Number ......................................................................................................................... 5 Comments/Narrative ............................................................................................................... 5 Abbreviations ..................................................................................................................... -
Where Have All the Fairies Gone? Gwyneth Evans
Volume 22 | Number 1 | Issue 83, Autumn Article 4 10-15-1997 Where Have All the Fairies Gone? Gwyneth Evans Follow this and additional works at: https://dc.swosu.edu/mythlore Recommended Citation Evans, Gwyneth (1997) "Where Have All the Fairies Gone?," Mythlore: A Journal of J.R.R. Tolkien, C.S. Lewis, Charles Williams, and Mythopoeic Literature: Vol. 22 : No. 1 , Article 4. Available at: https://dc.swosu.edu/mythlore/vol22/iss1/4 This Article is brought to you for free and open access by the Mythopoeic Society at SWOSU Digital Commons. It has been accepted for inclusion in Mythlore: A Journal of J.R.R. Tolkien, C.S. Lewis, Charles Williams, and Mythopoeic Literature by an authorized editor of SWOSU Digital Commons. An ADA compliant document is available upon request. For more information, please contact [email protected]. Where Have All the Fairies Gone? Abstract Examines a number of modern fantasy novels and other works which portray fairies, particularly in opposition to Victorian and Edwardian portrayals of fairies. Distinguishes between “neo-Victorian” and “ecological” fairies. Additional Keywords Byatt, A.S. Possession; Crowley, John. Little, Big; Fairies in literature; Fairies in motion pictures; Jones, Terry. Lady Cottington’s Pressed Fairy Book; Nature in literature; Wilson, A.N. Who Was Oswald Fish? This article is available in Mythlore: A Journal of J.R.R. Tolkien, C.S. Lewis, Charles Williams, and Mythopoeic Literature: https://dc.swosu.edu/mythlore/vol22/iss1/4 P a g e 12 I s s u e 8 3 A u t u m n 1 9 9 7 M y t h l o r e W here Have All the Fairies Gone? G wyneth Evans As we create gods — and goddesses — in our own Crowley's Little, Big present, in their very different ways, image, so we do the fairies: the shape and character a contrast and comparison between imagined characters an age attributes to its fairies tells us something about the of a Victorian and/or Edwardian past and contemporary preconceptions, taboos, longings and anxieties of that age. -
Flamingo Ingredients Chocolate Cupcakes Topped with Frosting
VIRTUAL CHOCOLATE-COVERED WEEKEND Flamingo Ingredients Chocolate cupcakes topped with frosting. ● Chocolate cupcakes (1 box/batch) ● Vanilla frosting (1 container) ● Pink food coloring ● Mini marshmallows (1 10.5 oz bag) ● Chocolate chips or black cake writing gel ● Lollipop sticks or straws Preparation 1. Make a batch of your favorite cupcakes. Once cool, arrange them on a platter in the shape of a flamin- go. 2. Mix the pink food coloring with the frosting in a bowl using a hand mixer. 3. Scoop the pink frosting into a piping bag or ziplock Inspired by our mosaiculture flamingo: with a corner cut off. Gently squeeze the frosting onto the cupcakes using a swirling motion. 4. Place marshmallows, chocolate chips and black cake gel on the “head” to make a face (see photo). Place straws for legs. 5. Eat and enjoy! Tips You could make flamingo faces on each cupcake in- stead by adding chocolate chips and other decorations in a face shape. Or decorate your cupcake to look like a creature of your own imagining. Our favorite food coloring McCormick’s “Nature’s Inspi- Ready in 1 hour ration” because it is made from plants instead of syn- Serves 20 people thetic dyes and has a vibrant pink color called “berry”. 10 of Hearts Ingredients Brownies topped with frosting and candy. ● Brownie mix (1 box/batch) ● Vanilla frosting (1 container) ● Black or red cake writing gel ● Candy hearts ● Lollipop sticks Preparation 1. Make a batch of your favorite brownies in a square or rectangular pan. 2. Once cool, cut the brownies into rectangles and slide 2 lollipop sticks halfway into a short end. -
Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A. -
VHA/Dod CLINICAL PRACTICE GUIDELINE for the MANAGEMENT of POSTOPERATIVE PAIN
VHA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF POSTOPERATIVE PAIN Veterans Health Administration Department of Defense Prepared by: THE MANAGEMENT OF POSTOPERATIVE PAIN Working Group with support from: The Office of Performance and Quality, VHA, Washington, DC & Quality Management Directorate, United States Army MEDCOM VERSION 1.2 JULY 2001/ UPDATE MAY 2002 VHA/DOD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF POSTOPERATIVE PAIN TABLE OF CONTENTS Version 1.2 Version 1.2 VHA/DoD Clinical Practice Guideline for the Management of Postoperative Pain TABLE OF CONTENTS INTRODUCTION A. ALGORITHM & ANNOTATIONS • Preoperative Pain Management.....................................................................................................1 • Postoperative Pain Management ...................................................................................................2 B. PAIN ASSESSMENT C. SITE-SPECIFIC PAIN MANAGEMENT • Summary Table: Site-Specific Pain Management Interventions ................................................1 • Head and Neck Surgery..................................................................................................................3 - Ophthalmic Surgery - Craniotomies Surgery - Radical Neck Surgery - Oral-maxillofacial • Thorax (Non-cardiac) Surgery.......................................................................................................9 - Thoracotomy - Mastectomy - Thoracoscopy • Thorax (Cardiac) Surgery............................................................................................................16 -
Primary Care & Tobacco Cessation Handbook: a Reference for Providers
Primary Care & Tobacco Cessation Handbook A Resource for Providers Primary Care & Tobacco Cessation Handbook A Resource for Providers Acknowledgements The provider manual Primary Care & Tobacco Cessation and the accompanying My Tobacco Cessation Workbook were developed by Julianne Himstreet, Pharm.D., BCPS. The author’s primary goal was to develop materials promoting tobacco cessation interventions, based on published principles of evidence- and consensus- based clinical practice, for use by primary care providers treating patients who use tobacco. With permission from the HIV and Smoking Cessation (HASC) Working Group, several materials used in the Primary Care & Tobacco Cessation provider manual were modified from HIV Provider Smoking Cessation Handbook. The U.S. Public Health Service Clinical Practice Guideline (Fiore, 2000) and the treatment model described by Richard Brown (2003) provided the foundation for their work and therefore indirectly ours as well.1 Many thanks to Kim Hamlett- Berry, Director of Tobacco & Health Policy in VHA Office of Mental Health Services for supporting this project and Leah Stockett for editing the manual and the workbook. In addition, much appreciation needs to be given to Dana Christofferson, Kim Hamlett- Berry, Pam Belperio, and Tim Chen for their editing and content contributions.1 1 Brown, R. A. (2003). Intensive behavioral treatment. In D. B. Abrams, R. Niaura, R. Brown, K. M. Emmons, M. G. Goldstein, & P. M. Monti, The tobacco dependence treatment handbook: A guide to best practices (pp. 118 -177). New York, NY: Guilford Press. Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Goldstein, M. G., Gritz, E. R., Heyman, R. -
Tobacco, E-Cigarettes and Alternative Products
Tobacco, E-Cigarettes and Alternative Products: Product Guide FOR PEDIATRIC PROVIDERS Although youth use of traditional cigarettes has declined in New York City (NYC), youth have turned to other products, including cigars, smokeless tobacco, and electronic cigarettes (e-cigarettes). These products are often flavored (such as with menthol) and almost always contain nicotine. Flavors are concerning because they can mask the harshness of tobacco, appeal to kids, and are often directly marketed to teens and preteens. NICOTINE can change the chemistry of the adolescent brain. It may affect learning ability and worsen memory and concentration. Youth are particularly vulnerable to nicotine dependence, which can occur even with occasional use. Nicotine may also affect the way the adolescent brain processes other drugs, like alcohol, cannabis and cocaine. The following is a list of selected products with their negative health effects to help you better counsel and guide your patients and their families. 2 TOBACCO: Smokeless Tobacco THE FACTS • Smokeless tobacco is not burned or smoked but always contains nicotine.* V It includes tobacco that can be sucked, chewed, spit or swallowed, depending on the product. PRODUCT NAME WHAT IT IS Chewing • Comes in loose leaf, plug or twist form Tobacco V Used by taking a piece and placing it between the cheek and gums; Also Known As may require spitting. Chew Snuff • Comes in moist, dry or packet (snus) form Also Known As V Moist snuff is used by taking a pinch and placing it between the lip Dip or cheek and gums; requires spitting. V Dry snuff is used by putting a pinch of powder in the mouth or by sniffing into the nose. -
Brick 10006390: Chewing Gum
Brick 10006390: Chewing Gum Definition Includes any products that can be described/observed as a type of gum made of chicle, a natural latex product, or synthetic equivalents such as polyisobutylene. Includes Bubble gum, which is a type of chewing gum, designed to be inflated out of the mouth as a bubble. Excludes Non–Chewing Gums and Anti–smoking treatments, and products that claim to be primarily Health Care or specific purpose gums such as Oral Care related like whiting, teeth cleansing. Diabetic Claim (20000056) Attribute Definition Indicates, with reference to the product branding, labelling or packaging, whether the product makes a claim to be suitable for consumption by consumers who have diabetes. Attribute Values NO (30002960) UNIDENTIFIED (30002518) YES (30002654) Special Occasion Claim (20000165) Attribute Definition Indicates, with reference to the product branding, labelling or packaging, the descriptive term that is used by the product manufacturer to identify whether the product is intended to be consumed for a special occasion. Attribute Values NO (30002960) UNIDENTIFIED (30002518) YES (30002654) Sugar Level Claim (20000174) Attribute Definition Indicates, with reference to the product branding, labelling or packaging, the descriptive term that is used by the product manufacturer to describe the level of sugar that is contained within the product. Page 1 of 15 Attribute Values CONTAINS SUGAR LOW SUGAR (30001471) UNCLASSIFIED (30002515) (30000744) SUGAR FREE (30002356) UNIDENTIFIED (30002518) Type of Chewing Gum (20002894) Attribute Definition Indicates, with reference to the product branding, labelling or packaging the descriptive term that is used by the product manufacturer to identify a particular type or variety of chewing gum. -
Oral Transmucosal Delivery for Improved Drug Bioavailability And
alenc uiv e & eq B io io B a f v o a i l l a Journal of a Vangara and Samala, J Bioequiv Availab 2015, 7:1 b n r i l i u t y o DOI: 10.4172/jbb.10000e58 J ISSN: 0975-0851 Bioequivalence & Bioavailability EditorialResearch Article OpenOpen Access Access Oral Transmucosal Delivery for Improved Drug Bioavailability and Patient Compliance Kiran K Vangara1* and Sushma Samala2 1Research and Development, Insys Therapeutics Inc., Chandler, AZ, USA 2Texas A&M University-Kingsville, Kingsville, TX, USA Since last 15 years the number of 505(b)(2) filings with new ODTs has been approved for different indications. The ODT market dosage forms for existing drug molecules at United states Food and is expected to exceed $13 billion by 2015 [5]. FDA defines ODT as Drug Administration (USFDA) has been increased tremendously. “a solid dosage form which contains a medicinal substance or active This is because of the tremendous increase in the developmental cost ingredient which disintegrates rapidly within a matter of seconds when of new chemical entities (NCE) and increased concerns about patient placed upon a tongue”. Various techniques such as direct compression, preferences and market demands for the novel unconventional dosage wet granulation, spray-drying, freeze-drying and sublimation were forms. These new dosage forms are being developed with improved used to prepare ODTs. Novel advanced technologies like Orasolv®, safety and efficacy together with patient compliance using novel drug Durasolv®, Wowtab®, Flashtab®, Zydis®, Flashdose®, Oraquick®, Lyoc®, delivery technologies [1]. Oral transmucosal drug delivery is rapidly Advatab®, Frosta®, Quick-Disc® and Nanomelt® are introduced by growing as a viable alternative for conventional oral dosage forms pharmaceutical companies for the preparation of ODTs. -
Creating a Smoke-Free Home
Creating a smoke-free home REFRESH How to Guide for Professionals Working with Families and Children SECTION 1 Introduction Page 3 SECTION 2 Who should use this guide? Page 4 SECTION 3 Why should you use this guide? Page 4 SECTION 4 How to use this guide Page 4 SECTION 5 What does the evidence say? Page 5 5.1 What is second-hand smoke? Page 5 5.2 Is smoking in the home and car common? Page 5 5.3 What do we know about exposure levels in the home and car? Page 5 5.4 Key facts on second-hand smoke and effects on children’s health Page 7 5.5 Tobacco smoke and house fires Page 7 SECTION 6 Common beliefs around second-hand smoke exposure Page 8 SECTION 7 The benefits of having a completely smoke-free home and car Page 10 SECTION 8 Hints and tips for parents on creating a smoke-free home and car Page 11 SECTION 9 Toxic breakdown of a cigarette Page 12 RAISING THE ISSUE - GUIDANCE FOR PROFESSIONALS Acknowledgements: SECTION 10 Practical tips on raising the issue and encouraging change Page 13 NHS Health Scotland Second-hand 10.1 The ‘REFRESH’ Flowchart Page 14 Smoke Coordinators Network NHS Rotherham SECTION 11 Raising the issue of second-hand smoke exposure in the home Page 15 Northfield Mother and Toddler 11.1 Overcoming parent barriers to creating a smoke-free home and car Page 15 Group, Aberdeen 11.2 Overcoming practitioner barriers to raising the issue with parents/carers Page 18 Gwen Russell Lorna McKenzie SECTION 12 Additional information on smoke-free homes Page 20 Kim Brannigan Lesley Young SECTION 13 Further support Page 20 SECTION 14 Further information……………………………………22 Page 20 For additional information on SECTION 15 REFRESH, please visit References Page 21 http//www.refreshproject.org.uk Getting started 1. -
Summary of Product Characteristics 1. Name Of
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Nicorette Mint 2 mg Compressed Lozenge 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each lozenge contains 2 mg nicotine (as nicotine resinate) For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Compressed Lozenge An oval, white to off-white tablet imprinted with an “n” on one side and “2” on the other side 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Nicorette Mint 2 mg Lozenges are to be used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms and cravings in smokers 18 years and above. Permanent cessation of tobacco use is the eventual objective. Nicorette Mint 2 mg Lozenges should preferably be used in conjunction with a behavioural support programme. Use of Nicorette Mint 2 mg Lozenge in smokers 12 – 17 years inclusive is at the discretion of a doctor: See section 4.2. 4.2 Posology and Method of Administration Posology Selecting the strength of lozenge to be used will depend on the smoking habits of the individual. Adults Nicorette Mint 2 mg Lozenges are suitable for smokers with low nicotine dependency e.g. those smoking their first cigarette of the day more than 30 minutes after waking up or those who smoke fewer than 20 cigarettes per day. Lozenges should not be used for more than 9 months. If users still feel the need for treatment, a physician should be consulted. Behavioural therapy advice and support will normally improve the success rate. 1/9 Paediatric population Children and adolescents Nicorette Mint 2 mg Lozenges should only be used by adolescents (12-17 years inclusive) with advice from a doctor.